Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, child: Medulloblastoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-22 of 22 for your search:
Start Over
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Phase: Phase III
Type: Supportive care, Treatment
Age: 3 to 21 at diagnosis
Trial IDs: ACNS0331, NCI-2009-00335, CDR0000365506, COG-ACNS0331, NCT00085735
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 3
Trial IDs: ACNS0334, NCI-2009-00338, CDR0000483683, COG-ACNS0334, NCT00336024
Chemotherapy and Radiation Therapy in Treating Young Patients with Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: ACNS0332, NCI-2009-00336, CDR0000511991, COG-ACNS0332, NCT00392327
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 30
Trial IDs: SOL-08131-L, NCI-2013-00790, 5056, MR00042551, OHSU-5056, NCT00983398
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
WEE1 inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients with Relapsed or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1312, NCI-2014-00547, NCT02095132
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: V0706, NCI-2014-00478, NCT00601003
Proton Beam Radiation Therapy in Treating Patients with Medulloblastoma and Pineoblastoma
Phase: Phase II
Type: Treatment
Age: 3 to 25
Trial IDs: DFCI 09-361, NCI-2010-01328, NCT01063114
Proton Beam Radiation Therapy in Treating Younger Patients with Brain Tumors
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 1 to 25
Trial IDs: 10-206, NCI-2011-00201, NCT01288235
Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 47 months old or younger
Trial IDs: ACNS1221, NCI-2013-02379, COG-ACNS1221, NCT02017964
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: AFLACST1502, NCI-2015-01637, IRB00082488, NCT02574728
Palbociclib Isethionate in Treating Younger Patients with Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: PBTC-042, NCI-2014-00640, NCT02255461
Pomalidomide in Treating Younger Patients with Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 20
Trial IDs: PBTC-043, NCI-2014-02182, CC-4047-PBTC-043, PPBTC-043_R04PAPP01, NCT02415153
Wild-Type Reovirus in Combination with Sargramostim in Treating Younger Patients with High-Grade Recurrent or Refractory Brain Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 10 to 21
Trial IDs: MC1472, NCI-2015-00665, MC1472 / Mayo IRB 14-006414, Mod14-006414-01, NCT02444546
Risk-Adapted Therapy in Treating Young Children with Brain Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 3 at diagnosis
Trial IDs: SJYC07, NCI-2011-01193, SJCRH-SJYC07, NCT00602667
Conditioning Therapy Followed by Stem Cell Transplant in Treating Patients with High Risk or Relapsed Solid, Central Nervous System, or Germ Cell Tumors
Phase: No phase specified
Type: Treatment
Age: 70 and under
Trial IDs: 2011OC057, NCI-2013-02265, 1107M02641, MT2011-09C, NCT01505569
Cyclophosphamide or Thalidomide after Stem Cell Transplant in Treating Younger Patients with Solid Tumors
Phase: No phase specified
Type: Treatment
Age: 5 to 21
Trial IDs: 201209088, NCI-2012-01541, NCT01661400
Clinical and Molecular Risk-Directed Craniospinal Irradiation and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Medulloblastoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21 at diagnosis
Trial IDs: SJMB12, NCI-2013-01125, NCT01878617
Fluorine F 18 Fluorodopa PET/MRI in Predicting Response in Younger Patients with Central Nervous System Tumors
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 21 and under
Trial IDs: 201303069, NCI-2013-00822, NCT01999270
Surgery and Combination Chemotherapy in Treating Younger Patients with Non-metastatic Standard-Risk Medulloblastoma
Phase: No phase specified
Type: Treatment
Age: 3 to 18
Trial IDs: J1403, NCI-2014-01870, CIR00004694, NA_00091840, NA_00091840 / CIR00004694, NCT02212574
Start Over